We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Platelet-to-lymphocyte ratio might predict the response to dupilumab treatment for patients with nasal polyposis.
- Authors
Brkic, Faris F.; Liu, David T.; Rücklinger, Iris; Campion, Nicholas James; Bartosik, Tina Josefin; Vyskocil, Erich; Stanek, Victoria; Tu, Aldine; Gangl, Katharina; Schneider, Sven
- Abstract
Background: Dupilumab is a monoclonal antibody against interleukin 4 receptor alpha and has proven to be clinically effective in treating patients with chronic rhinosinusitis with nasal polyps (CRSwNP). However, a certain number of patients are non- or partial responders. This study aims to investigate the relevance of inflammatory markers with regard to therapy response to dupilumab in CRSwNP patients. Methods: All patients with CRSwNP treated with dupilumab at a tertiary healthcare center with available pretreatment inflammatory markers were included. The values of pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were associated with the outcome. Patients were stratified according to the respective median value (> median was considered high). The binary logistic regression was performed with regard to total treatment response (post-treatment total nasal polyp score (NPS) 0). Results: A total of 65 CRSwNP patients with available pretreatment peripheral blood values were included in the study. The mean pre- and post-treatment total NPS values were 4.3 ± 1.9 and 1.2 ± 1.6, respectively. High PLR (> 131.2) was independently associated with a 3.9-fold higher probability of reaching the NPS value of 0 in the multivariable analysis. On the other hand, High NLR (> 1.9) did not significantly associate with the outcome. Conclusions: The current study provides insights into the potential positive predictive value of the high PLR (> 131.2) in CRSwNP patients regarding treatment with dupilumab. There is a need for further prospective studies for validation of these results, especially in cohorts of patients with severe CRSwNP.
- Subjects
AUSTRIA; THERAPEUTIC use of monoclonal antibodies; NASAL polyps; BIOMARKERS; PLATELET lymphocyte ratio; RETROSPECTIVE studies; TERTIARY care; TREATMENT effectiveness; NEUTROPHIL lymphocyte ratio; SINUSITIS; DESCRIPTIVE statistics; INFLAMMATORY mediators; LOGISTIC regression analysis; DATA analysis software; BLOOD cell count
- Publication
Journal of Otolaryngology -- Head & Neck Surgery, 2023, Vol 52, Issue 1, p1
- ISSN
0707-7270
- Publication type
Article
- DOI
10.1186/s40463-023-00660-7